急性髓细胞白血病患者CD96和CD123的表达及对预后的意义
|
摘要
目的检测CD96、CD123在急性髓细胞白血病(AML)患者中的表达,探讨其与AML疗效和预后的关系。方法选取156例AML患者为观察对象,选取同期该院健康体检者150例作为对照组。采用流式细胞术检测CD96、CD123表达情况,并分析CD96、CD123表达与化疗疗效的关系。结果 AML患者CD96、CD123的阳性表达率与对照组比较,差异有统计学意义(P <0.05);AML患者中CD96、CD123阳性表达的缓解率均低于阴性表达者(P <0.05);AML患者中CD96、CD123阳性表达的生存率均低于阴性表达者(P <0.05);AML患者中CD96、CD123阳性表达的化疗后感染、化疗后复发发生率均高于阴性表达者(P <0.05);AML患者中CD96、CD123阳性表达的中位生存期均低于阴性表达者(P<0.05)。结论 CD96、CD123在AML中均有不同程度的表达,其阳性表达可能与原发耐药或复发进展有关,可作为判断AML患者预后的相关指标。
Objective To study the expression of CD96 and CD123 in acute myelocytic leukemia(AML)patients and their potential clinical significance. Methods Totally 156 AML patients were selected as subjects. Flow cytometry was performed to detect the expression of CD96 and CD123. Relationship between CD96/CD123 and clinical characteristics were analyzed. Results The positive expression rates of CD96 and CD123 were significantly increased in AML group when compared with control group(P < 0.05). Remission rates and survival in patients with positive expression of CD96 and CD123 were dramatically lowered when compared with other AML patients(P < 0.05). Patients with double positive expression of CD96 and CD123 experienced increased incidence of postchemotherapy infection and recurrence rates(P < 0.05) when compared with those in other AML patients(P < 0.05).Conclusions CD96 and CD123 are differentially expressed in AML patients. The positive expression of CD96 and CD123 may be related to poor outcome.
Objective To study the expression of CD96 and CD123 in acute myelocytic leukemia(AML)patients and their potential clinical significance. Methods Totally 156 AML patients were selected as subjects. Flow cytometry was performed to detect the expression of CD96 and CD123. Relationship between CD96/CD123 and clinical characteristics were analyzed. Results The positive expression rates of CD96 and CD123 were significantly increased in AML group when compared with control group(P < 0.05). Remission rates and survival in patients with positive expression of CD96 and CD123 were dramatically lowered when compared with other AML patients(P < 0.05). Patients with double positive expression of CD96 and CD123 experienced increased incidence of postchemotherapy infection and recurrence rates(P < 0.05) when compared with those in other AML patients(P < 0.05).Conclusions CD96 and CD123 are differentially expressed in AML patients. The positive expression of CD96 and CD123 may be related to poor outcome.
引文
[1]SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2015[J].CA Cancer J Clin,2015,65(1):5-29.
[2]吕心路,王金湖.CD123与CD47在急性髓细胞白血病干细胞中的表达及临床意义[J].浙江临床医学,2016,18(12):2188-2190.
[3]韦湘,杨丽萍.急性白血病患者骨髓干细胞CD96,CD123的表达及与预后的相关性[J].江西医药,2017,52(5):422-424.
[4]LIU K,ZHU M,HUANG Y,et al.CD123 and its potential clinical application in leukemias[J].Life Sci,2015,1(122):59-64.
[5]ARBER D A,ORAZI A,HASSERJIAN R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood,2016,127(20):2391-2405.
[6]EHNINGER A,KRAMER M,R?LLIG C,et al.Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia[J].Blood Cancer J,2014,13(4):e218.
[7]MARDIROS A,DOS S C,MCDONALD T,et al.T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia[J].Blood,2013,122(18):3138-3148.
[8]HE S Z,BUSFIELD S,RITCHIE D S,et al.A Phase l study of the safety,pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed,refractory or highrisk acute myeloid leukemia[J].Leuk Ly7 mphoma,2015,56(5):1406-1415.
[9]LI L J,TAO J L,FU R,et al.Increased CD34+CD38-CD123+cells in myelodysplastic syndrome displaying malignant features similar to those in AML[J].Int J Hematol,2014,100(1):60-69.
[10]DU W,HU Y,LU C,et al.Cluster of differentiation 96 as a leukemia stem cell-specific marker and a factor for prognosis evaluation in leukemia[J].Mol Clin Oncol,2015,3(4):833-838.
[11]JIANG Y,XU P,YAO D,et al.CD33,CD96 and death associated protein kinase(DAPK)expression are associated with the survival rate and/or response to the chemotherapy in the patients with acute myeloid leukemia(AML)[J].Med Sci Monit,2017,9(23):1725-1732.
[12]DING Y,GAO H,ZHANG Q.The biomarkers of leukemia stem cells in acute myeloid leukemia[J].Stem Cell Investig,2017,2(4):19.
[13]YABUSHITA T,SATAKE H,MARUOKA H,et al.Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia[J].Leuk Lymphoma,2017,18:1-8.
[2]吕心路,王金湖.CD123与CD47在急性髓细胞白血病干细胞中的表达及临床意义[J].浙江临床医学,2016,18(12):2188-2190.
[3]韦湘,杨丽萍.急性白血病患者骨髓干细胞CD96,CD123的表达及与预后的相关性[J].江西医药,2017,52(5):422-424.
[4]LIU K,ZHU M,HUANG Y,et al.CD123 and its potential clinical application in leukemias[J].Life Sci,2015,1(122):59-64.
[5]ARBER D A,ORAZI A,HASSERJIAN R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood,2016,127(20):2391-2405.
[6]EHNINGER A,KRAMER M,R?LLIG C,et al.Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia[J].Blood Cancer J,2014,13(4):e218.
[7]MARDIROS A,DOS S C,MCDONALD T,et al.T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia[J].Blood,2013,122(18):3138-3148.
[8]HE S Z,BUSFIELD S,RITCHIE D S,et al.A Phase l study of the safety,pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed,refractory or highrisk acute myeloid leukemia[J].Leuk Ly7 mphoma,2015,56(5):1406-1415.
[9]LI L J,TAO J L,FU R,et al.Increased CD34+CD38-CD123+cells in myelodysplastic syndrome displaying malignant features similar to those in AML[J].Int J Hematol,2014,100(1):60-69.
[10]DU W,HU Y,LU C,et al.Cluster of differentiation 96 as a leukemia stem cell-specific marker and a factor for prognosis evaluation in leukemia[J].Mol Clin Oncol,2015,3(4):833-838.
[11]JIANG Y,XU P,YAO D,et al.CD33,CD96 and death associated protein kinase(DAPK)expression are associated with the survival rate and/or response to the chemotherapy in the patients with acute myeloid leukemia(AML)[J].Med Sci Monit,2017,9(23):1725-1732.
[12]DING Y,GAO H,ZHANG Q.The biomarkers of leukemia stem cells in acute myeloid leukemia[J].Stem Cell Investig,2017,2(4):19.
[13]YABUSHITA T,SATAKE H,MARUOKA H,et al.Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia[J].Leuk Lymphoma,2017,18:1-8.